CD4 and HIV-1 infection: CD4-binding site broadly neutralizing antibodies, such as VRC01 [58,59,60], N6 [61] (ClinicalTrials.gov Identifier: NCT03538626), and 3BNC117 [62,63,64], are currently at different stages of clinical trials for HIV-1 infection treatment and/or prevention.